Phaseline

Companies › Intellia Therapeutics

Intellia Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 3, 1 Phase 1; Immunology, Neurology, Cardiovascular; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTLA-2002–Phase 3Hereditary AngioedemaMay 2027
nexiguran ziclumeran (NTLA-2001)
in vivo CRISPR/Cas9 gene editing targeting TTR gene
TTRPhase 3Neuromuscular Disease; Transthyretin Amyloidosis (ATTR) With CardiomyopathyJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05120830NTLA-2002Phase 1Hereditary AngioedemaImmunologyMay 2027
NCT06672237nexiguran ziclumeran (NTLA-2001)Phase 3Neuromuscular DiseaseNeurologyJul 2027
NCT06634420NTLA-2002Phase 3Hereditary AngioedemaImmunologySep 2027
NCT06128629nexiguran ziclumeran (NTLA-2001)Phase 3Transthyretin Amyloidosis (ATTR) With CardiomyopathyCardiovascularDec 2027

From the company's SEC filings

Cash and short-term investments of $474m on 2026-09-30; operating cash outflow about $384m a year; runway about 15 months at that burn, to Dec 2027; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TTR (1)

Companies with the same targets

Alnylam Pharmaceuticals AstraZeneca Novo Nordisk Neurimmune Eidos Therapeutics, a BridgeBio company Ionis Pharmaceuticals Qilu Pharmaceutical

Companies built like this

Eidos Therapeutics, a BridgeBio company Abeona Therapeutics Supergene Kedrion Cabaletta Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.